prikaz prve stranice dokumenta Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9—A Narrative Review
  Download
PDF 377.01 KB
Scientific paper - Review paper
Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9—A Narrative Review
Cardiovascular Therapeutics, 2022 (2022); 8129513. https://doi.org/10.1155/2022/8129513
Merćep, Iveta; Friščić, Nikolina; Strikić, Dominik; Reiner, Željko

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Merćep, I., Friščić, N., Strikić, D. & Reiner, Ž. (2022). Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9—A Narrative Review. Cardiovascular Therapeutics, 2022.. doi: 10.1155/2022/8129513

Merćep, Iveta, et al. "Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9—A Narrative Review." Cardiovascular Therapeutics, vol. 2022, 2022. https://doi.org/10.1155/2022/8129513

Merćep, Iveta, Nikolina Friščić, Dominik Strikić and Željko Reiner. "Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9—A Narrative Review." Cardiovascular Therapeutics 2022 (2022). https://doi.org/10.1155/2022/8129513

Merćep, I., et al. (2022) 'Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9—A Narrative Review', Cardiovascular Therapeutics, 2022. doi: 10.1155/2022/8129513

Merćep I, Friščić N, Strikić D, Reiner Ž. Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9—A Narrative Review. Cardiovascular Therapeutics [Internet]. 2022 February 10 [cited 2024 November 30];2022. doi: 10.1155/2022/8129513

I. Merćep, N. Friščić, D. Strikić and Ž. Reiner, "Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9—A Narrative Review", Cardiovascular Therapeutics, vol. 2022, February 2022. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:539871. [Accessed: 30 November 2024]

Metadata
Title (english)Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9—A Narrative Review
AuthorIveta Merćep
AuthorNikolina Friščić
AuthorDominik Strikić
AuthorŽeljko Reiner
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (english)
As dyslipidemias remain one of the main risk factors for developing cardiovascular disease, the question of maintaining optimal lipid levels with pharmacotherapy remains a subject of interest worldwide. In contrast to conventional pharmacotherapy, human monoclonal antibodies directed against proprotein convertase subtilisin/kexin type 9 (PSCK9) and small interfering RNA- (siRNA-) based drug targeting PCSK9 represent a new strategy for managing lipid disorders and reducing cardiovascular risk. Inclisiran is a long-acting, synthetic siRNA that targets hepatic production of PCSK9 and consequently causes a reduction in LDL-C concentrations by approximately 50% compared to placebo. The structural modification of inclisiran has led to better stability and prolonged biological activity of the drug. The main advantage over conventional pharmacotherapy and anti-PCSK9 monoclonal antibodies is its favorable administration regimen (0–90–180 days), which should lead to much better compliance. Clinical trials conducted so far have confirmed the tolerability and efficacy of inclisiran in long-term PCSK9 and LDL-C level reductions. Moreover, a short-term follow-up on the safety of inclisiran showed a relatively good safety profile of the drug. However, it is still of great importance for ongoing and forthcoming clinical trials to be continued on a larger group of patients in order to assess long-term tolerability, efficacy, and safety of inclisiran.
Keywords (english)
Languageenglish
Publication typeScientific paper - Review paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleCardiovascular Therapeutics
Numberingvol. 2022, 8129513
p-ISSN1755-5914
e-ISSN1755-5922
DOIhttps://doi.org/10.1155/2022/8129513
URN:NBNurn:nbn:hr:105:539871
Publication2022-02-10
Document URLhttps://www.hindawi.com/journals/cdtp/2022/8129513/
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2022-10-10 09:10:05